{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:05Z","timestamp":1792705025465,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Before the introduction of targeted therapy and immunotherapy, patients with metastatic non-small-cell lung cancer (NSCLC) had a 5-year overall survival (OS) rate of up to 10%. After the positive results of KEYNOTE-024, pembrolizumab was approved in a first-line setting for patients with metastatic NSCLC and PD-L1 \u2265 50%. A small number of patients had a durable response to immunotherapy, and so far it has not been discovered who will benefit. The aim of this study was to investigate the efficacy of first-line pembrolizumab in patients with locally advanced and metastatic NSCLC with high PD-L1 expression in a real-world setting. We enrolled 35 patients with locally advanced and metastatic NSCLC who had PD-L1 \u2265 50%. Progression-free survival was 9 months, 95% CI (2.6\u201315.4). Overall survival was 14 months, 95% CI (0\u201328.5). Five-year OS rate for the whole group of patients was 20%, and the six-year OS rate was 17.2%. Immunotherapy was a revolution in the treatment of NSCLC. We still do not know which patients will benefit from immunotherapy, but patients who do respond may experience long-term outcomes.<\/jats:p>","DOI":"10.3390\/curroncol32040229","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:59:06Z","timestamp":1744689546000},"page":"229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-9346","authenticated-orcid":false,"given":"Vesna","family":"\u0106eriman Krsti\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Soldatovi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milija","family":"Gaji\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Samard\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3286-3663","authenticated-orcid":false,"given":"Ru\u017ea","family":"Stevi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Center for Radiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1970","authenticated-orcid":false,"given":"Nikola","family":"\u010coli\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Center for Radiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4861-4189","authenticated-orcid":false,"given":"Katarina","family":"Luki\u0107","sequence":"additional","affiliation":[{"name":"Center for Radiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"\u0160eha","sequence":"additional","affiliation":[{"name":"Clinic for Neurosurgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Radon\u010di\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavko","family":"Stameni\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-0731","authenticated-orcid":false,"given":"Milan","family":"Savi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Clinic for Thoracic Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Milenkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"},{"name":"Clinic for Thoracic Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brankica","family":"Milo\u0161evi\u0107 Mara\u010di\u0107","sequence":"additional","affiliation":[{"name":"Institute of Oncology and Radiology Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Jovanovi\u0107","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic \u201cAkta Medica\u201d, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mco.2023.2701","article-title":"Progress in the research of immunotherapy-related hyperprogression (Review)","volume":"20","author":"Qi","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients with Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"Kudaba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients with Advanced Non\u2013Small-Cell Lung Cancer Treated with Pembrolizumab: Results From the PhaseIKEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.3390\/curroncol30060402","article-title":"Real-World Outcomes of Stage IV NSCLC with PD-L1 \u2265 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy","volume":"30","author":"Rittberg","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s10637-019-00843-y","article-title":"Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: A multicenter retrospective cohort study (HOPE-001)","volume":"37","author":"Tamiya","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0300891620926244","article-title":"Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: A retrospective observational study","volume":"107","author":"Cavaille","year":"2021","journal-title":"Tumori."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/jitc-2020-001007","article-title":"Outcomes to first-line pembrolizumab in patients with PD-L1-high (\u226550%) non-small cell lung cancer and a poor performance status","volume":"8","author":"Alessi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/cam4.2806","article-title":"First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 \u2265 50% in a multicenter real-life cohort: The PEMBREIZH study","volume":"9","author":"Amrane","year":"2020","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-022-03232-2","article-title":"First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score \u2265 \u200950%) advanced non-small cell lung cancer in the real world: Impact in brain metastasis: A national French multicentric cohort (ESCKEYP GFPC study)","volume":"72","author":"Descourt","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","article-title":"Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u226550","volume":"69","author":"Cortellini","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/j.cllc.2020.02.017","article-title":"Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression","volume":"21","author":"Tambo","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2143","DOI":"10.1002\/onco.13909","article-title":"Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center","volume":"26","author":"Knez","year":"2021","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez Gal\u00e1n, R., Prado-Mel, E., P\u00e9rez-Moreno, M.A., Caballano-Infantes, E., and Flores Moreno, S. (2021). Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. Biology, 10.","DOI":"10.3390\/biology10090890"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cramer-van der Welle, C.M., Verschueren, M.V., Tonn, M., Peters, B.J.M., Schramel, F.M.N.H., Klungel, O.H., Groen, H.J.M., van de Garde, E.M.W., and Santeon NSCLC Study Group (2021). Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85696-3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive Disease in Patients with Advanced Non-Small Cell Lung Cancer Treated with PD-1\/PD-L1 Inhibitors or with Single-Agent Chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","article-title":"Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitor","volume":"14","author":"Kim","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-Fc\/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1\/PD-L1 Blockade","volume":"25","author":"Moro","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","article-title":"Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria","volume":"26","author":"Matos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_30","first-page":"00179","article-title":"Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: A retrospective analysis","volume":"5","author":"Hurkmans","year":"2019","journal-title":"ERJ Open Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2019.01.010","article-title":"Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report","volume":"129","author":"Tunali","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Arasanz, H., Zuazo, M., Bocanegra, A., Gato, M., Mart\u00ednez-Aguillo, M., Morilla, I., Fern\u00e1ndez, G., Hern\u00e1ndez, B., L\u00f3pez, P., and Alberdi, N. (2020). Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 12.","DOI":"10.3390\/cancers12020344"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CAD.0000000000000864","article-title":"Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study","volume":"31","author":"Petrioli","year":"2020","journal-title":"Anticancer Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1759-7714.13272","article-title":"Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)","volume":"11","author":"Arrieta","year":"2020","journal-title":"Thorac. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:14:36Z","timestamp":1760030076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/4\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["curroncol32040229"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32040229","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}